Pharmaceutical compositions comprising an aromatse inhibitors
The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
1. A low-dose pharmaceutical composition, comprising a blended mixture comprising
(a) a therapeutically effective amount of 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile which amount is from about 0.01 mg to about 3 mg per dosage unit;
(b) one or more filler;
(c) one or more disintegrant;
(d) one or more lubricant, and
(e) one or more glidant.
2. A pharmaceutical composition according to claim 1 , wherein said therapeutically effective amount of 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile is about 0.1 mg, about 0.05 mg, about 0.1 mg, about 0.3 mg, about 0.5 mg, about 1 mg, about 2 mg, or about 3 mg per dosage unit.
3. A pharmaceutical composition according to claim 1 , wherein said filler is selected from one or more of microcrystalline cellulose; low-substituted hydroxypropyl cellulose; hydroxyethyl cellulose; hydroxypropyl methyl cellulose; carbohydrates, such as sugars, sugar alcohols, starches, starch derivatives, for example sucrose, lactose, dextrose, saccharose, glucose, sorbitol, mannitol, xylitol, potato starch, maize starch, rice starch, wheat starch or amylopectin; tricalcium phosphate, calcium hydrogen phosphate, calcium sulfate, dibasic calcium phosphates, and magnesium oxide.
4. A pharmaceutical composition according to claim 1 , wherein said filler is selected from one or more of microcrystalline cellulose, lactose, and maize starch.
5. A pharmaceutical composition according to claim 1 , wherein said disintegrant is selected from one or more of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosscarmellose sodium, Sodium Starch Glycolate, alginic acid, sodium alginate and guar gum.
6. A pharmaceutical composition according to claim 1 , wherein said lubricant is selected from one or more of magnesium stearate, aluminium silicate, calcium silicate, stearic acid, cutina, PEG 4000-8000, and talc.
7. A pharmaceutical composition according to claim 1 , wherein said glidant is selected from one or more of colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, and talc.
8. The pharmaceutical composition of claim 2 wherein said filler is selected from the group consisting of microcrystalline cellulose, lactose and maize starch, and mixtures thereof, said disintegrant is Sodium Starch Glycolate (SSG), said lubricant is magnesium stearate, and said glidant is colloidal silicon dioxide.
9. The pharmaceutical composition of claim 5 wherein said disintegrant is Sodium Starch Glycolate.
10. The pharmaceutical composition of claim 6 wherein said lubricant is magnesium stearate.
11. The pharmaceutical composition of claim 7 wherein said glidant is colloidal silicon dioxide.
12. The pharmaceutical composition according to claim 1 , wherein said therapeutically effective amount of 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile is from about 0.01 mg to up to about 3.0 mg per dosage unit; said filler is selected from one or more of microcrystalline cellulose, lactose, and maize starch; said disintegrant is selected from one of more of carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosscarmellose sodium, Sodium Starch Glycolate, alginic acid, sodium alginate and guar gum; said lubricant is selected from one or more of magnesium stearate, aluminium silicate, calcium silicate, stearic acid, cutina, PEG 4000-8000, and talc; said glidant is selected from one or more of colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, and talc.
13. A pharmaceutical composition according to claim 1 wherein
said filler is employed in an amount ranging from about 80% to about 96% by weight of the dosage unit content,
said disintegrant is employed in an amount ranging from about 3% to about 6% by weight of the dosage unit content,
said lubricant is employed in an amount ranging from about 0.25% to about 5% by weight of the dosage unit content, and
said glidant is employed in an amount ranging from about 0.25% to about 1% by weight of the doage unit content.
14. A pharmaceutical composition of claim 1 , wherein 4, 4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile is in a solid oral dosage unit and provides a T max of 0.5-2 hrs.
15. A pharmaceutical composition of claim 14 , wherein the T max is 1 hour.
16. A pharmaceutical composition of claim 1 , wherein the blend uniformity is between 95% and 101%.
17. A pharmaceutical composition of claim 1 , wherein the content uniformity of the blend in the dosage unit is between 97% and 104%.